Eli Lilly and Company (LLY.MX)
Mexico - Mexico Delayed Price. Currency in MXN
Add to watchlist
At close: 10:41AM CST
| Previous Close | 16,562.49 |
| Open | 16,135.35 |
| Bid | 15,000.00 x 100 |
| Ask | 16,695.00 x 10000 |
| Day's Range | 16,562.49 - 16,562.49 |
| 52 Week Range | 7,452.75 - 17,062.39 |
| Volume | |
| Avg. Volume | 248 |
| Market Cap | 14.913T |
| Beta (5Y Monthly) | 0.41 |
| PE Ratio (TTM) | 133.33 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 94.17 (0.57%) |
| Ex-Dividend Date | Aug 15, 2024 |
| 1y Target Est | N/A |
- Zacks
NVO, LLY Slip After Study Links Obesity Drug Use to Vision Loss
A new study led by investigators of a Harvard-affiliated teaching hospital found that Novo Nordisk's (NVO) GLP-1 drugs Ozempic and Wegovy could be linked to rare cases of vision loss.
- Investor's Business Daily
Novo, Lilly Tumble After Study Ties Blindness Disorder To Weight-Loss Drugs
Novo Nordisk stock skidded Wednesday after a new study suggests its diabetes and weight-loss drug can lead to a blindness-causing disease.
- Yahoo Finance Video
Weight-loss drugs linked to rare vision loss: Harvard study
Novo Nordisk (NVO) and Eli Lilly (LLY) shares dip in reaction to a Harvard study that found GLP-1 weight-loss drugs Ozempic and Wegovy could be linked to rare cases of vision loss. Yahoo Finance health reporter Anjalee Khemlani explains the study's findings. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Luke Carberry Mogan.
© 2024 Yahoo. All rights reserved.